In the effort to continuously strengthen the position with customers and be able to serve the IVD Diagnostics industry with quality diagnostics solutions, SSI Diagnostica Group is unifying its commercial sales and marketing regions for the diagnostics portfolio – kits and consumables. Cara Felish will join SSI Diagnostica Group as new head of this commercial division and step into the Global Leadership Team. Cara has extensive experience from the diagnostic, biotech, and pharmaceutical industry in various leadership positions from commercial operation and excellence, sales, and marketing.

“Our main goal is to serve the clinical diagnostic market in the effort of preventing, monitoring, and diagnosing people – supporting better treatment outcomes for patients globally. To accelerate and deliver on our exciting and ambitious growth agenda, we are happy Cara is joining SSI Diagnostica Group to strengthen the global commercial voice of our sales and marketing regions both internally and externally. Our business priorities should be founded on customer needs – and for this we need an aligned global commercial agenda and clear priorities for the global business to accelerate our effort in serving the market with our diagnostic solutions. With Cara’s proven leadership and focus on commercial excellence from both IVD and pharma industry, I am sure this will be a tremendous step in delivering on our priorities.” says Christina Lindved, Group CEO.

SSI Diagnostica Group is owned by Adelis Equity and embarked on a new 5-year strategy and growth plan in 2023 with the introduction of a new Executive and Leadership team.